Skip to main content

NCT01795703 - A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy

A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy


Data Specification

Not Available


Annotated CRF

Not Available

Product Info

Generic Name
Abiraterone acetate
Product Name
ZYTIGA¬ģ
Therapeutic Area
Cancers and Other Neoplasms
Enrollment
47
% Female
0.0%
% White
N/A
Product Class
Hormones
Sponsor Protocol Number
JNJ-212082-JPN-202
Data Partner
Johnson & Johnson
Condition Studied
Neoplasms, Prostatic
Mean/Median Age (Years)
72.0

Supporting Documentation

Clinical Study Report
Collected Datasets
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.